Scholar Rock to Host Investor Day on May 22, 2024
Scholar Rock (NASDAQ: SRRK) will host an Investor Day on May 22, 2024, starting at 8:30 a.m. ET in New York City. The event will feature presentations from the executive management team on their myostatin inhibition programs targeting spinal muscular atrophy (SMA) and obesity. Renowned experts Dr. Ania Jastreboff of Yale School of Medicine and Dr. Diana Castro of the Neurology & Neuromuscular Care Center will also provide insights. Participants can access a live webcast and slide presentation via Scholar Rock's website, with a replay available for 90 days.
- Hosting an Investor Day can bolster shareholder confidence and provide transparency.
- Focus on innovative treatments for SMA and obesity highlights potential market opportunities.
- Involvement of distinguished experts from Yale and Neurology & Neuromuscular Care Center adds credibility.
- No new clinical data or financial results were disclosed, limiting immediate investor insights.
- The announcement does not address current financial performance or potential risks.
The Investor Day will feature presentations by members of Scholar Rock’s executive management team about the Company’s myostatin inhibition programs in SMA and obesity, as well as commentary from key opinion leaders Dr. Ania Jastreboff, M.D., Ph.D., Associate Professor of Medicine (Endocrinology) Yale School of Medicine, and Diana Castro, M.D., Founder of the Neurology & Neuromuscular Care Center and Neurology Rare Disease Center.
A slide presentation and live audio webcast of the event may be accessed by visiting the Investors & Media section of the Scholar Rock website at http://investors.scholarrock.com. An archived replay of the webcast will be available on the Company’s website for approximately 90 days.
About Scholar Rock
Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGFβ) superfamily of cell proteins and named for the visual resemblance of a scholar rock to protein structures, the clinical-stage company is focused on advancing innovative treatments where protein growth factors are fundamental. Over the past decade, Scholar Rock has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role.
Scholar Rock is the only company to show clinical proof-of-concept for a muscle-targeted treatment in spinal muscular atrophy (SMA). This commitment to unlocking fundamentally different therapeutic approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through traditional therapies, Scholar Rock works every day to create new possibilities for patients. Learn more about our approach at ScholarRock.com and follow @ScholarRock and on LinkedIn.
Availability of Other Information About Scholar Rock
Investors and others should note that we communicate with our investors and the public using our company website www.scholarrock.com, including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on Twitter and LinkedIn. The information that we post on our website or on Twitter or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Scholar Rock® is a registered trademark of Scholar Rock, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240514302331/en/
Scholar Rock:
Investors
Rushmie Nofsinger
Scholar Rock
rnofsinger@scholarrock.com
ir@scholarrock.com
857-259-5573
Media
Molly MacLeod
Scholar Rock
mmacleod@scholarrock.com
media@scholarrock.com
802-579-599
Source: Scholar Rock
FAQ
When is Scholar Rock's Investor Day?
What will be discussed at Scholar Rock's Investor Day 2024?
How can I access the webcast of Scholar Rock's Investor Day?
Who are the key opinion leaders speaking at Scholar Rock's Investor Day?
